CRISPR therapy STX-1150 could replace daily cholesterol pills with a single dose, reducing LDL by 50% for 18+ months using ...

In this retrospective study, researchers explored whether reducing osimertinib dose in EGFR-mutated metastatic NSCLC patients who experienced adverse events would worsen survival.

President Donald Trump said he takes more aspirin daily than his doctors recommend, continuing the routine for years and referring to it as a “superstition.” “They say aspirin is good for thinning out ...

Children with peanut allergies may not need large doses of peanut oral immunotherapy (OIT) to build protection to peanut, finds a new study led by The Hospital for Sick Children (SickKids) and ...

Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced an agreement with the U.S. government to provide Eliquis® (apixaban), an oral anticoagulant relied upon by millions of Americans daily, for free ...

Now, before I get into it, I will preface this review by saying my liver was fine to begin with. And if my liver were to give me issues, I would go to a doctor (as you should too!) before ever turning ...

Using less ipilimumab appears to make melanoma immunotherapy both safer and more effective, with dramatically better response and survival outcomes. The findings suggest that reducing side effects may ...

A preliminary study found that adults with type 2 diabetes and a moderate or high risk of cardiovascular disease were less likely to experience a serious cardiovascular event when taking low-dose ...

BROWNSBURG, IN – A medication long known for its use in substance abuse treatment is getting a second life in the world of functional medicine, offering a new approach for people suffering from ...

GameSpot may get a commission from retail offers. Most Arc Raiders quests send you topside to investigate, gather resources, or obtain some type of intel. This trend continues with Reduced to Rubble, ...

Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...

SAN FRANCISCO, CA—Administering low-dose alteplase directly into the artery prior to PCI in patients with STEMI and a large thrombus burden fails to lower the risk of a range of outcomes, including ...